Genetic test identifies at-risk hypertensives
Genetic test identifies at-risk hypertensives
Myriad Genetics, based in Salt Lake City, has launched a new genetic test called CardiaRisk that will help physicians identify which hypertensive patients are at a significantly increased risk of developing cardiovascular disease. The test will also identify which patients are likely to respond to low-salt diet therapy and antihypertensive drug therapy.
CardiaRisk identifies the presence of a genetic variation of the AGT gene. Hypertensive patients with the variant gene are 43% more likely to progress, and their condition is more likely to occur earlier in life and become more severe.
The test takes about two weeks to perform and costs $395.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.